---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-078800"
form_type: "8-K"
ticker: "MREO"
cik: "0001719714"
company_name: "Mereo BioPharma Group plc"
filed_at: "2024-03-27T23:59:59+00:00"
generated_at: "2026-06-04T07:17:20.282115+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mereo BioPharma reports FY2023 revenue $10M, net loss $29.5M; cash $57.4M funds ops into 2026

## Summary
- Revenue $10.0M from Ultragenyx milestone and ReproNovo upfront; net loss $29.5M vs $42.2M in 2022.
- Cash $57.4M; net cash burn Q4 2023 $6.7M; expected runway into 2026 supporting current plans.
- Setrusumab Orbit (Phase 2/3) enrollment completes Q1 2024; Cosmic (Phase 3) H1 2024, by partner Ultragenyx.
- Alvelestat Phase 3 plan with partner around end 2024; FDA aligned on SGRQ primary endpoint.
- Leflutrozole licensed to ReproNovo for up to $64.25M milestones plus tiered mid-single digit royalties.

## SEC filing metadata
- accession: 0001193125-24-078800
- form_type: 8-K
- ticker: MREO
- cik: 0001719714
- company_name: Mereo BioPharma Group plc
- filed_at: 2024-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719714/000119312524078800/0001193125-24-078800-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719714/000119312524078800/d807451d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-078800
- JSON: https://secwatch.observer/filing/0001193125-24-078800.json
- Plain text: https://secwatch.observer/filing/0001193125-24-078800.txt

## Key facts
- Earnings Releases
  Mereo BioPharma Group plc reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: On March 27, 2024, Mereo BioPharma Group plc announced its financial results for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719714/000119312524078800/0001193125-24-078800-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.